Johnson & Johnson (NYSE:JNJ), is expanding its system of life-science incubators to include a new, 30,000-square-foot space in South San Francisco, the company said Wednesday. Johnson & Johnson (NYSE:JNJ), net profit margin is 69.10% and weekly performance is -0.33%. On last trading day company shares ended up $100.58. Analysts mean target price for the company is $104.84. Johnson & Johnson (NYSE:JNJ), distance from 50-day simple moving average (SMA50) is 2.83%.
On May 07, 2014, Merck & Co Inc has agreed to sell its consumer care business to Germany’s Bayer AG for $14.2 billion, adding to a string of major cross-border healthcare deals. Merck & Co., Inc. (NYSE:MRK), fell 0.04% in last trading session and ended the day on $55.87. MRK, Gross Margin is 61.30% and its return on assets is 5.70%. Merck & Co., Inc. (NYSE:MRK), quarterly performance is 1.56%.
On May 15, 2014, VIVUS, Inc. (NASDAQ:VVUS), announced that a poster describing results of an analysis of the association between weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV and annual concomitant medication costs will be presented at the AACE 23rd Annual Scientific & Clinical Congress at the Paris Las Vegas Hotel, Las Vegas, NV.VIVUS, Inc. (NASDAQ:VVUS), shares moved down 2.42% in last trading session and was closed at $4.83, while trading in range of $4.82 – 5.05. VIVUS, Inc. (NASDAQ:VVUS), year to date (YTD) performance is -46.81%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock dropped 0.31% to $6.39. The company on May 12 provided a corporate update and reported financial results for the first quarter ended March 31, 2014. The company’s first quarter revenues totaled $6.8 million, including $2.9 million in net product sales of BELVIQ, of which $2.7 million represented 31.5% of Eisai’s net product sales and $0.2 million related to redemptions of the 15-day free voucher. Net loss was $25.3 million, or $0.12 per share. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ended the last trading day at $6.43. Company weekly volatility is calculated as 4.91% and price to cash ratio as 6.36. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), showed a negative weekly performance of 10.57%.
Merck KGaA(ADR) (OTCMKTS:MKGAY), the maker of the Erbitux cancer drug, forecast a “moderate increase” in sales and profit in 2014 because of the acquisition of AZ Electronic Materials SA (AZEM), a chemicals supplier to the electronics industry. Merck KGaA(ADR) (OTCMKTS:MKGAY), on last trading day company shares ended up $57.40.
Leave a Reply